


# QPLC Epitomics lung cancer test for early detection

For the discovery of disease specific biomarkers beyond the resolution of individual proteins.

Area	Diagnostics
Headquarter	Debrecen, Hungary
Parent company	Biosystems International Kft.

Relationship with the parent company	Completely separated
Countries of operation	UK
Founding year	2018
Status	Prototype
Incubator programme	N/A
Approvals	CE marking 510K or CLIA
Patents	PTC/EP2019/08642
Awards	N/A
Revenue (last yr)	N/A
Sources of revenue	N/A
Funds raised	€ 4.5M
Currently raising:	€ 3M

By combining BSI's monoclonal antibodies (mAbs) from the QuantiPlasma™ libraries with existing immunoassay techniques, BSI can identify differences in the level of epitopes between cancer patients and cancer free controls with greatly enhanced accuracy compared to classical cancer biomarkers. The added value of the epitomics solution lies in that BSI can mine the biomarker sources not available to competitors. The key constituent of BSI's technology is that it enables BSI to profile molecular changes beyond the resolution of individual proteins. Intensive and completed R&D activities let BSI to the discovery of epitope variability specific for lung cancer. Survival of lung cancer is dependent on early detection. BSI's QPLC lung cancer test if combined with computer tomography presents a definitive advantage as compared to imaging alone.



Interested? Get in touch